Merrill Lynch & Company is acting as sole book-running manager and J.P. Morgan Securities Inc. is co-lead manager, with JMP Securities LLC and Leerink Swann & Company acting as co-managers for the offering. The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus related to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.
About Orexigen Therapeutics
Orexigen(TM) Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which it plans to advance into Phase III clinical trials in the first half of 2007, and Excalia(TM), which is in late Phase II clinical trials.
Contacts:
Corporate Media Orexigen Therapeutics, Inc. GendeLLindheim BioCom Partners Graham Cooper Stephen Gendel Chief Financial Officer 212-918-4650 858-436-8600
Source: Orexigen Therapeutics, Inc.
